We are live on ! Find out more

ARK Genomic Revolution ETF

ARKG

Market cap $2B

47.85 USD

+0.14

0.29%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

47.34

-0.51

1.07%

1 day

0.29%

5 days

5.26%

1 month

8.65%

3 months

37.18%

6 months

80.23%

Year to date

63.98%

1 year

80.23%

5 years

-41.27%

10 years

145.51%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 75%

Neutral 25%

Negative 0%

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Zacks Investment Research

Best-Performing ETF Areas of August

August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.

Best-Performing ETF Areas of August

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

24/7 Wall Street

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

Zacks Investment Research

Best ETF Areas of June

Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.

Best ETF Areas of June

June's Top ETFs: Biotech & China Semiconductors Surge

June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.

June's Top ETFs: Biotech & China Semiconductors Surge

Zacks Investment Research

Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.

Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simultaneously engaging with potential acquirers.

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Cathie Wood, Bill Ackman Share 3 Stock Investments In Common: Can You Guess What They Are?

Two of the most well-known investors are betting on the same three Magnificent Seven stocks. Here's a look at the stocks owned by both Cathie Wood and Bill Ackman.

Cathie Wood, Bill Ackman Share 3 Stock Investments In Common: Can You Guess What They Are?

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Medical Technology Stocks: Innovation Endures As Valuations Reset

See News Rankings

Price charts implemented using Lightweight Charts™